Johnson & Johnson says it may have the results of its late-stage experimental coronavirus vaccine trial sooner than expected. Johnson & Johnson chief scientific officer Dr Paul Stoffels said the results of the company's late-stage coronavirus vaccine trial may be sooner than expected and is targeted for January 2021. Pictured: The experimental vaccine being produced by Johnson & JohnsonJ&J's vaccine only requires one dose and combines genetic material from the new virus with the virus that causes colds to induce an immune response. The latest contract is priced at roughly $10 per vaccine dose, including a previous $456 million the government promised to J&J for vaccine development in March. The announcement states that, under the deal, the US government can order an additional 200 million dose of the vaccine.

Source: Daily Mail December 08, 2020 16:01 UTC